Get the Stockscreener App
4.65
10.49%
-0.545
After Hours:
4.65
Aldeyra Therapeutics Inc stock is traded at $4.65, with a volume of 2.60M.
It is down -10.49% in the last 24 hours and down -8.64% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.195
Open:
$5.12
24h Volume:
2.60M
Relative Volume:
2.45
Market Cap:
$279.76M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.20
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-15.45%
1M Performance:
-8.64%
6M Performance:
-16.37%
1Y Performance:
-24.39%
1-Day Range:
$4.365
$5.12
1-Week Range:
$4.365
$5.74
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
4.65 | 312.55M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
HC Wainwright Issues Pessimistic Estimate for ALDX Earnings - MarketBeat
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving AverageHere's What Happened - MarketBeat
How volatile is Aldeyra Therapeutics Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - mfd.ru
EBITDA per share of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ: ALDX) outlines reproxalap, ADX-2191 and AbbVie deal - Stock Titan
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-02-28 16:42:08 - baoquankhu1.vn
Coya Therapeutics, Inc. (COYA) upgraded to buy: What does it mean for the stock? - MSN
Aldeyra Therapeutics, Inc.Common Stock (NQ: ALDX - The Chronicle-Journal
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference - MarketBeat
Overview of FDA Regulatory Developments - Intellectia AI
Aldeyra Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Understanding Momentum Shifts in (ALDX) - Stock Traders Daily
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Zacks Investment Research
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan
Perceptive fund discloses 7% Aldeyra (ALDX) ownership stake - Stock Titan
Biotech Stocks Facing FDA Decision In March 2026 - RTTNews
Does Aldeyra Therapeutics Inc. have a sustainable dividendJuly 2025 Reactions & Daily Profit Maximizing Tips - mfd.ru
Aldeyra's Dry Eye Therapy Faces FDA In MarchWill The Third Time Be A Charm? - RTTNews
Published on: 2026-02-12 20:14:42 - baoquankhu1.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Avoiding Lag: Real-Time Signals in (ALDX) Movement - Stock Traders Daily
Wall Street analysts predict a 65.75% upside in Aldeyra Therapeutics (ALDX): Here's what you should know - MSN
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know - Finviz
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? - Yahoo Finance
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Discipline and Rules-Based Execution in ALDX Response - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Earnings Recap: Is Aldeyra Therapeutics Inc exposed to political riskQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Market Review: Does Aldeyra Therapeutics Inc have consistent dividend growthJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Will BOOT benefit from green energy policies2025 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Thera - The National Law Review
ATA Creativity Global Among 3 Promising Penny Stocks - Yahoo Finance
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update - MarketBeat
Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily
FDA Extends Review Timeline for Aldeyra's Dry Eye Drug Candidate () - aktiencheck.de
Support Test: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus
Head to Head Review: Scienture (NASDAQ:SCNX) & Aldeyra Therapeutics (NASDAQ:ALDX) - Defense World
Analysis Recap: Is Aldeyra Therapeutics Inc stock trending bullish2025 Momentum Check & Community Trade Idea Sharing Platform - baoquankhu1.vn
Insider Buy: Does National Energy Services Reunited Corp Equity Warrant stock reflect fundamentals2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Trend Review: Is Envirotech Vehicles Inc in accumulation or distribution phaseJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):